After having discussed a possible application with the Expert in Residence, applicants must discuss their potential application with their usual OUI contact. Their OUI contact will be able to help advise them on completing the IP section of the application form, (specifically identifying and describing Background IP necessary for the proposed project) and discuss any questions they may have about the terms and conditions, or obligations associated with a LAB282 award.

LAB282 is managed operationally on behalf of the University and OUI by Dr Christine Whyte, Principal Licensing & Ventures Manager. She is happy to answer any questions relating to the LAB282 scheme from University academics, where they do not have an existing OUI contact.

DR CHRISTINE WHYTE

Principal Licensing & Ventures Manager

Christine has responsibility for managing the LAB282 initiative. 

She obtained a first class honours degree in Microbiology from the University of Bristol then obtained a DPhil at the University of Oxford, studying gene expression in bacteria.

Prior to joining OUI in 2007, Christine held roles in Unilever, the diagnostics company Oxoid (now part of Thermo Fisher Scientific), Cancer Research Technology and Oxxon Therapeutics

Angela Calvert

DR ANGELA CALVERT


Deputy Head of Licensing & Ventures, Life Sciences,
Oxford University Innovation Ltd.

Angela leads a team of highly experienced Licensing and Ventures professionals in Life Sciences to successfully translate technologies from the University of Oxford.  This includes management of early-stage therapeutic development opportunities through the identification, protection and management of IP, defining commercial & IP strategies, assessing translational and investment funding and negotiation of license and spin out corporate agreements.  She is the lead for OUI on the LAB282 and Conservation Venture Studio initiatives, represents OU as a Board Observer in Osler Diagnostics and a in range of key stakeholder relationships.  She has previously work in business development roles and holds a PhD and MSC in Plant Genetics.

Lab282 Partners

Slide LAB282 is a partnership between the University of Oxford, Oxford University Innovation Ltd, Oxford Sciences Innovation plc (OSI) and Evotec AG, created to identify and develop new approaches to treating disease.

Privacy Policy | Cookie Policy

© LAB282 2021. All rights reserved
LAB282 is a partnership between the University of Oxford, Oxford University Innovation Ltd, Oxford Sciences Innovation plc (OSI) and Evotec AG, created to identify and develop new approaches to treating disease.

Privacy Policy | Cookie Policy

© LAB282 2021. All rights reserved